Biospringer Acquires PTX Food Corp's Bacterial Fermentation IP, Signals Broader Ingredient Shift
Biospringer's acquisition of bacterial fermentation IP from PTX Food Corp expands its capabilities beyond yeast, enabling a wider array of fermented ingredient solutions for the food and beverage sector.
London, United Kingdom — 21 May 2026
Biospringer, a division of Lesaffre, has acquired specific intellectual property and proprietary technologies from PTX Food Corp, a specialist in bacterial fermentation processes. This strategic move, reported by Food Ingredients First, significantly expands Biospringer's capabilities beyond its traditional yeast fermentation focus. PTX Food Corp is co-owned by Zilor and Biorigin, with Biospringer already holding a majority stake in Biorigin, streamlining the integration of these advanced bacterial fermentation technologies.
The integration of PTX Food Corp's expertise with Biospringer's established manufacturing infrastructure and international commercial reach is expected to accelerate innovation in fermented food ingredient solutions. This expansion aims to deliver a broader range of high-performance, customer-focused ingredients to the global food and beverage industry, leveraging microbial technology for improved taste, nutrition, texture, and preservation. The deal also includes assets related to the Bioenhance product line, suggesting an immediate commercial application for the acquired technology.
This acquisition highlights a wider industry trend of ingredient manufacturers expanding their microbial technology portfolios beyond conventional yeast. Investments are increasingly directed towards diverse fermentation-derived solutions, including bacterial and enzyme-based platforms, to meet growing demand for clean-label, plant-based, and enhanced sensory experiences in food products.
What this means for United Kingdom
UK brand owners must monitor Biospringer's new bacterial fermentation offerings for potential ingredient advantages, particularly for plant-based and functional food product development. This could offer novel opportunities for product differentiation and improved sensory attributes, driving consumer acceptance in a competitive market. Procurement teams should engage with Biospringer by Q1 2027 to understand new ingredient availability, pricing structures, and minimum order quantities, assessing potential impacts on ex-factory costs by up to 5%. Regulatory teams will need to scrutinise novel bacterial-derived ingredients for specific FSA compliance requirements and Novel Food authorisations, which could extend product development timelines by 12-18 months. Early engagement with ingredient suppliers is crucial for securing supply and navigating reformulation opportunities.
Carmel Arruda, Biospringer's General Manager, stated that the acquisition aligns with their commitment to delivering innovative products. This sentiment underscores a competitive drive among major ingredient players to dominate the expanding fermentation-derived ingredient sector, which is critical for future product innovation in areas like flavour enhancement and alternative proteins. The move positions Biospringer to offer more tailored solutions across key markets, including Europe.
Brand owners increasingly rely on contract-manufacturing partners such as Supplement Factory to navigate these requirements.